Houlihan Lokey enters its July 27 earnings report in an interesting spot: the stock pulled back 2.3% on Tuesday to $139.12, yet UBS lifted its price target on the same day, and several boutique banking peers are running well ahead on the week.
The options market shows a mild but genuine increase in defensive hedging. The put/call ratio has climbed to 0.114, running above its 20-day average of 0.082 by roughly 1.7 standard deviations — not extreme, but the highest it has been over the past month. The move matters in context: for most of June, the PCR was pinned below 0.08, reflecting near-total call dominance. The drift higher into late June and early July suggests some investors are quietly adding downside protection ahead of the print, even as the broader tone remains constructive. Short interest is not the story here — it stands at just 3% of free float and has fallen 27% over the past month, unwinding a cluster of bearish positions that briefly appeared in late May. Borrow availability is extraordinarily loose at over 7,000% of short interest, meaning there are roughly 71 shares available for every one currently borrowed. Cost to borrow is 0.52%, up modestly on the month but well within normal range. The lending market is not signaling any stress.
The Street retains a broadly positive lean on HLI, even as targets have drifted lower through 2026. UBS today nudged its target to $161 while holding a Neutral rating — a small constructive move from a cautious house. Morgan Stanley and Goldman Sachs both maintain positive ratings (Overweight and Buy respectively) though each trimmed targets in the March–April period. The mean price target across the Street is $171.63, implying roughly 23% upside from current levels — a wide gap that reflects both the stock's 10% decline from its early-year highs and persistent bull conviction from the bulge bracket. HLI's forward earnings yield factor ranks well within its sector, and the dividend score is in the 97th percentile of the universe, though the dividend history in the data is stale and should be treated as informational background rather than current yield guidance. The PE multiple has compressed to 15.7x, down about 1.75 turns over the past month, making the valuation case modestly more attractive than it was in early June.
Peers tell a more energetic week-on-week story. PJT Partners surged 16.2% on the week and Moelis added 11%, while Stifel Financial rose 10.3%. HLI's 3.7% weekly gain is respectable but notably lags this cohort, which has benefited from renewed M&A sentiment. That relative underperformance is consistent with HLI's recent stock-score history, which points to a franchise strong on growth fundamentals but trailing on near-term price momentum. Evercore and Lazard are both tracking closer to HLI's pace, up roughly 3.6% and 3.4% respectively.
Insider activity from May is worth noting. Eight insiders — including the CEO, CFO, and Executive Co-Chairman — sold shares on May 15 at around $150, generating combined proceeds of roughly $8.6 million net over the 90-day window. The sells happened near the stock's recent highs, and with the price now at $139, the cluster of insider supply at $150 is a level to keep in mind heading into results. The July 27 print will be the next real test: the prior earnings reaction was a one-day gain of 2.2%, but the print before that saw a 3% drop. The range is tight, but the spread between the mean analyst target and the current price leaves the directional debate wide open.
See the live data behind this article on ORTEX.
Open HLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Houlihan Lokey reports fiscal fourth-quarter results on May 8 with options traders leaning notably bullish — an unusual posture for a financial-advisory firm heading into a print where M&A visibility has been clouded…
Houlihan Lokey walks into its Thursday earnings call with options traders positioned about as bullishly as they've been all year — a sharp contrast to the cautious tone set by a bruising week for the advisory…
